title: Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients.
abstract: BACKGROUND
  The aim of this study was to investigate the clinical efficacy of RetroNectin-activated cytokine-induced killer cell (R-CIK) therapy following conventional therapies in patients with metastatic brain tumors.
  
  
  METHODS
  This study included 20 patients with metastatic brain tumors. Patients received R-CIK therapy following conventional therapies (including chemotherapy and target therapy). Progression-free survival (PFS), overall survival (OS), and prognostic factors were evaluated.
  
  
  RESULTS
  Of the 4 breast cancer patients in our cohort, 2 remained alive and 2 died. Of the 14 non-small cell lung cancer (all adenocarcinoma) patients, 3 had a partial response, 8 had stable disease, and 3 had progressive disease after receiving R-CIKs. The overall response rate was 21.4% (3/14), and the disease control rate was 78.6% (11/14). The median PFS and OS were 7.7 months (95% confidence interval (CI) 3-16.5 months) and 12.6 months (95% CI 6-21 months), respectively.
  
  
  CONCLUSIONS
  R-CIKs combined with conventional therapies could improve the prognosis of metastatic brain tumor patients, especially of those with adenocarcinoma of the lung.
authors: Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
authors: Wei
authors: W
authors: Li
authors: Yaomei
authors: Y
authors: Wang
authors: Lingdi
authors: L
authors: Zhao
authors: Linping
authors: L
authors: Xu
authors: Yong
authors: Y
authors: Zhang
authors: Ling
authors: L
authors: Mai
authors: Quanli
authors: Q
authors: Gao
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000276:immunology / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000473:pathology / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D055612:Cytokine-Induced Killer Cells / Q000187:drug effects* / Q000276:immunology*; D003601:Cytotoxicity Tests, Immunologic; D018450:Disease Progression; D005260:Female; D005353:Fibronectins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005353:Fibronectins; D011994:Recombinant Proteins; C545354:retronectin